ENTRY       D11990                      Drug
NAME        Lisocabtagene maraleucel (USAN/INN);
            Breyanzi (TN)
PRODUCT     BREYANZI (Juno Therapeutics)
REMARK      Product: D11990<US>
EFFICACY    Antineoplastic, Anti-CD19 CAR-T cell
  DISEASE   Diffuse large B-cell lymphoma, not otherwise specified [DS:H02434]
            Follicular lymphoma [DS:H01613]
  TYPE      Cellular therapy product, CAR-T cell therapy
TARGET      CD19 [HSA:930] [KO:K06465]
  PATHWAY   hsa04151(930)  PI3K-Akt signaling pathway
            hsa04640(930)  Hematopoietic cell lineage
            hsa04662(930)  B cell receptor signaling pathway
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD19
                 D11990  Lisocabtagene maraleucel (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D11990
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11990
             Cellular and gene therapy products
              D11990
            New drug approvals in Japan [br08318.html]
             Cellular and gene therapy products
              D11990
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11990
///
